Cargando…

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

While programmed cell death 1 (PD-1) inhibitors have shown clear anti-tumor efficacy in several solid tumors, prior results in men with metastatic castration resistant prostate cancer (mCRPC) showed no evidence of activity. Here we report unexpected antitumor activity seen in mCRPC patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graff, Julie N., Alumkal, Joshi J., Drake, Charles G., Thomas, George V., Redmond, William L., Farhad, Mohammad, Cetnar, Jeremy P., Ey, Frederick S., Bergan, Raymond C., Slottke, Rachel, Beer, Tomasz M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper: Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288150/ https://www.ncbi.nlm.nih.gov/pubmed/27429197 http://dx.doi.org/10.18632/oncotarget.10547

Ejemplares similares

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
por: Graff, Julie N, et al.
Publicado: (2020)

Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic castrate resistant prostate cancer progressing on enzalutamide and initiating treatment with anti-PD-1 (pembrolizumab)
por: Peiffer, Lauren B., et al.
Publicado: (2022)

Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer
por: Podolak, Jennifer, et al.
Publicado: (2017)

Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
por: Smith, Rebecca, et al.
Publicado: (2020)

Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity
por: Monga, Jitender, et al.
Publicado: (2021)

Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer
por: King, Carly J., et al.
Publicado: (2017)

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
por: Luo, Jia, et al.
Publicado: (2016)

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
por: Bishop, Jennifer L., et al.
Publicado: (2014)

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
por: Alumkal, Joshi J., et al.
Publicado: (2020)

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
por: Coleman, Daniel J., et al.
Publicado: (2016)

Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer
por: Siddiqui, Bilal A., et al.
Publicado: (2022)

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
por: Xu, Pengfei, et al.
Publicado: (2023)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

Molecular mechanisms of enzalutamide resistance in prostate cancer
por: Blatt, Eliot B., et al.
Publicado: (2019)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials
por: Tombal, Bertrand F., et al.
Publicado: (2021)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
por: Vander Ark, Alexandra, et al.
Publicado: (2018)

Molecular determinants for enzalutamide-induced transcription in prostate cancer
por: Yuan, Fuwen, et al.
Publicado: (2019)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
por: Lopes, Nair, et al.
Publicado: (2021)

Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer
por: Detert Oude Weme, S. E. H., et al.
Publicado: (2023)

Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases
por: Schoen, Martin W., et al.
Publicado: (2022)

Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide
por: Greene, John, et al.
Publicado: (2019)

Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases
por: Schoen, Martin W., et al.
Publicado: (2023)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
por: Wright, Timothy C., et al.
Publicado: (2021)

Local and systemic modulation of the PD-L1 pathway is a novel mechanism of Enzalutamide resistance in castration-resistant prostate cancer
por: Bishop, Jennifer, et al.
Publicado: (2014)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Enzalutamide: A New Agent for the Prostate Cancer Treatment Armamentarium
por: McCutcheon, Stephanie B.
Publicado: (2013)

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
por: Linder, Simon, et al.
Publicado: (2018)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018)

A comprehensive characterization of the transcriptome in enzalutamide resistance prostate cancer
por: Wang, Lili, et al.
Publicado: (2021)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
por: Staniszewska, Magdalena, et al.
Publicado: (2021)

Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
por: Schultz, Neil M., et al.
Publicado: (2020)

Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity
por: Westbrook, Thomas C., et al.
Publicado: (2022)

hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro
por: Lim, Marvin C. J., et al.
Publicado: (2021)

The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials
por: Tombal, Bertrand, et al.
Publicado: (2021)

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
por: Rana, Dikshyanta, et al.
Publicado: (2021)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023)

Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
por: Golshayan, Ali R, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_93d6981u01cu6n6ks44dhf3fdu